Andrew Wolf, MD, discusses the growing costs, treatment advances, and geographic disparities in multiple sclerosis care.

With over 1 million Americans affected by multiple sclerosis (MS), we wanted to learn more about its symptoms, particularly ...

Researchers have identified two experimental medications that may be able to promote myelin repair in people with MS, a study ...

Multiple sclerosis, which affects around one in 500 people in Switzerland, is an autoimmune disease in which immune cells ...

Updates in relapsing-remitting MS from ECTRIMS 2025 examine lifestyle interventions, anti-CD20 therapies, efficacy of ...

Once-yearly infusions of rituximab are as effective as twice-yearly dosing for sustained control of MS in a new phase 3 trial ...

Share on Pinterest A recent study reports that starting treatment at the first signs of MS symptoms could help slow disease progression. Jennifer Blount/Getty Images A recent study finds getting ...

A novel program provided evidence that addressing long-known disparities in high-efficacy multiple sclerosis (MS) treatment for minority populations is a solvable problem. The program, presented by ...

Patients suspecting they have multiple sclerosis (MS) are encountering significant delays in accessing specialist care, with ...

Discover the groundbreaking medical trial offering new hope for autoimmune diseases and the first courageous patient behind its success.

An update from BioNxt Solutions ( ($TSE:BNXT) ) is now available. BioNxt Solutions Inc., a bioscience company specializing in innovative drug ...

Research presented recently at the ECTRIMS Congress 2025 highlights the patient perspective on menopause and MS.